Julie Chun
Family Medicine · Bossier City, LANPI 1245641554
Payments from drug & device makers
Across 79 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$426
- Pfizer$139
- AbbVie$126
- Genentech USA, Inc.$88
- Boehringer Ingelheim$84
- Lilly USA, LLC$78
- plus $359 from 13 others
What the payments were for
- Food & beverage$1,300100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $426 |
| Pfizer | 9 | $139 |
| AbbVie(2 entities) | 8 | $126 |
| Genentech USA, Inc. | 5 | $88 |
| Boehringer Ingelheim | 6 | $84 |
| Lilly USA, LLC | 5 | $78 |
| Mylan Specialty L.p. | 3 | $66 |
| Abbott | 3 | $56 |
| Tactile Systems Technology Inc | 1 | $39 |
| Medtronic | 1 | $32 |
| AstraZeneca | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Roche Diagnostics Corporation | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
How this compares
$1,300 in reported general payments places this provider in the 60th percentile of 1,469 family medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $128,601 |
| JardianceEmpagliflozin | 81 | $63,614 |
| FarxigaDapagliflozin Propanediol | 29 | $42,750 |
| EliquisApixaban | 36 | $38,843 |
| MounjaroTirzepatide | 32 | $37,329 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $27,748 |
| TrulicityDulaglutide | 20 | $18,380 |
| JanuviaSitagliptin Phosphate | 22 | $16,370 |
| MyrbetriqMirabegron | 18 | $11,477 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $10,388 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $10,012 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,328 |
| PremarinEstrogens, Conjugated | 15 | $2,940 |
| Gabapentin | 132 | $2,388 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 114 | $2,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $426 | $128,601107 claims |
| Boehringer IngelheimJardiance | $84 | $63,61481 claims |
| Lilly USA, LLCMounjaro, Trulicity | $78 | $55,70952 claims |
| AstraZenecaFarxiga | $28 | $42,75029 claims |
| PfizerEliquis, Premarin | $139 | $41,78351 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Bossier City
- Clint WilsonBossier City$208K
- Jason MilliganBossier City$15K
- Michael AngeloBossier City$15K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.